摘要
我们的目的是调查在健康受试者和阿尔茨海默氏病患者(AD)或轻度认知障碍患者(MCI)静息状态网络间的活动及其连通性(RSNS)。磁共振成像(MRI)和静息态MRI对诊断为AD的患者(n = 18)或MCI(n = 16)和健康受试者(n = 18)与之匹配的人口学特征(年龄、性别、教育程度)。独立成分分析和Granger因果分析(GCA)应用于图像处理中。我们计算‘In + Out degree’为每个RSN。然后,我们调查了‘In + Out degree’的每个脑网络和认知行为数据之间的关系。采用最优匹配的方法获得了最强。五个RSNs的核心区在AD,MCI和健康对照组之间类似,但在这五个RSNs之内的活性在AD和MCI组较健康对照组显著降低(P<0.01,错误发现率修正)。该结果表明,五个RSNs水平之间的连接,特别是从默认模式网络的连通性(DMN)的水平,略低于MCI患者和显著低于AD患者相比于健康受试者。相反,存储网络和在AD和MCI患者的执行控制网络之间的联系增加明显。DMN的“In + Out degree”与蒙特利尔认知评估量表评分呈负相关(R=-0.43, P<0.05)。总之,在RSNs之内的活性与RSNs之间的连接性在AD患者,MCI患者,和正常人之间是不同的;这些结果为阿尔茨海默病的诊断及疾病进展的测量和揭示疾病的发病机制提供了影像学依据。
关键词: 阿尔茨海默病(AD)、轻度认知障碍(MCI),老年痴呆症,静息状态网络(RSNS),静息状态下的功能磁共振成像(RS-fMRI),独立成分分析(ICA)、Granger因果分析(GCA)。
Current Alzheimer Research
Title:Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment
Volume: 13 Issue: 3
Author(s): Yu Chen, Hao Yan, Zaizhu Han, Yanchao Bi, Hongyan Chen, Jia Liu, Meiru Wu, Yongjun Wang, Yumei Zhang
Affiliation:
关键词: 阿尔茨海默病(AD)、轻度认知障碍(MCI),老年痴呆症,静息状态网络(RSNS),静息状态下的功能磁共振成像(RS-fMRI),独立成分分析(ICA)、Granger因果分析(GCA)。
摘要: We aimed to investigate the activity within and the connectivity between resting state networks (RSNs) in healthy subjects and patients with Alzheimer’s disease (AD) or mild cognitive impairment (MCI). Magnetic resonance imaging (MRI) and resting-state MRI were performed on patients diagnosed with AD (n=18) or MCI (n=16) and on healthy subjects (n=18) with matching demographic characteristics (age, sex, and education level). Independent component analysis and Granger causality analysis (GCA) were used during image postprocessing. We calculated ‘In + Out degree’ for each RSN. Then, we investigated the relationships between “In + Out degree” of each brain network and the cognitive behavioural data. RSNs were obtained using the optimal matching method. The core areas of the five RSNs were similar between the AD, MCI, and healthy control groups, but the activity within these five RSNs was significantly lower in the AD and MCI groups than in the healthy control group (P<0.01, false discovery rate corrected). The GCA results showed that the connectivity between the five RSNs, particularly the connectivity from the default mode network (DMN) to the other RSNs, was slightly lower in MCI patients and was significantly lower in AD patients than in healthy subjects. In contrast, increased connectivity was evident between the memory network and the executive control network in the AD and MCI patients. The “In + Out degree” of the DMN negatively correlated with the Montreal Cognitive Assessment score in AD patients (R=-0.43, P<0.05). In conclusion, the activity within RSNs and the connectivity between RSNs differed between AD patients, MCI patients, and normal individuals; these results provide an imaging reference for the diagnosis of AD and the measurement of disease progression and reveal insight into the pathogenesis of AD.
Export Options
About this article
Cite this article as:
Yu Chen, Hao Yan, Zaizhu Han, Yanchao Bi, Hongyan Chen, Jia Liu, Meiru Wu, Yongjun Wang, Yumei Zhang , Functional Activity and Connectivity Differences of Five Resting-State Networks in Patients with Alzheimer’s Disease or Mild Cognitive Impairment, Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/156720501303160217113858
DOI https://dx.doi.org/10.2174/156720501303160217113858 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Assessment In Vitro of a Novel Therapeutic Strategy for Glioma, Combining Herpes Simplex Virus HSV1716-mediated Oncolysis with Gene Transfer and Targeted Radiotherapy
Medicinal Chemistry Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Comparison of Anticancer Properties of Annona muricata L. Acetonic and Methanolic Leaf Extracts
The Natural Products Journal Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers
Current Cancer Drug Targets Techniques and Methods for In Vivo MRI Monitoring of Exogenous and Endogenous Neural Stem Cell-Mediated Brain Repair
Recent Patents on Regenerative Medicine Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds Gold Nanoparticle-Based Drug Delivery Platform for Antineoplastic Chemotherapy
Current Drug Metabolism Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain
Current Nanoscience Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry Pro-Oxidant Milieu Blunts Scissors: Insight into Tumor Progression, Drug Resistance, and Novel Druggable Targets
Current Pharmaceutical Design Iron Oxide Nanoparticles Synthesized Via Green Tea Extract for Doxorubicin Delivery
Current Nanoscience An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry Discovery and Applications of Disulfide-Rich Cyclic Peptides
Current Topics in Medicinal Chemistry Histone Variants and Composition in the Developing Brain: Should MeCP2 Care?
Current Topics in Medicinal Chemistry MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy Targeting the EGFR-family for Therapy: Biological Challenges and Clinical Perspective
Current Pharmaceutical Design